ProKidney Reports Business Updates and First Quarter 2024 Financial Results [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
ProKidney Corp. - Class A Ordinary Shares (PROK)
Company Research
Source: Yahoo! Finance
An investor call to provide a perspective on CKD with Dr. Arnold Silva and Dr. Steven Coca and a recap of the RMCL-002 data is planned for May 28, 2024 On schedule to resume manufacturing and PROACT 1 Phase 3 trial, commence PROACT 2 Phase 3 trial, and readout interim results from the ongoing REGEN-007 Phase 2 trial in mid-2024 Strengthened leadership team with appointment of two key hires across Clinical and Technical Operations Ended the first quarter with $329 million in cash and cash equivalents and marketable securities, supporting operating plans into Q4 2025 WINSTON-SALEM, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported business updates and financial results for the first quarter ended March 31, 2024. “With the full results of RMCL-002 to be presented at the European Renal Association Congress later t
Show less
Read more
Impact Snapshot
Event Time:
PROK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PROK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PROK alerts
High impacting ProKidney Corp. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PROK
News
- ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024 [Yahoo! Finance]Yahoo! Finance
- ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024GlobeNewswire
- We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- ProKidney Reports Business Updates and First Quarter 2024 Financial ResultsGlobeNewswire
- Diabetic Kidney Disease (DKD) - Market Insight, Epidemiology and Market Forecast - 2032 [Yahoo! Finance]Yahoo! Finance
PROK
Earnings
- 5/10/24 - Beat
PROK
Sec Filings
- 5/22/24 - Form 4
- 5/20/24 - Form 144
- 5/16/24 - Form 4
- PROK's page on the SEC website